@heiseonline bei den andern 50% ist es Zufall wenn jemand beim Doktor ans Telefon geht.
Ob die KKS jetzt #placebos finanziert oder #ki. Hilft wahrscheinlich gleich viel. 🤷🏻‍♀️
My #hypochondria's so bad my doctor prescribes me broad spectrum #placebos.

Placebos

My hypochondria’s so bad my doctor prescribes me broad spectrum placebos.

#AucklandComedy #Comedy #Hypochondria #NZComedy #Placebos

Shuffling through my #music, the #WhiteStripes' "Girl, You Have No Faith in Medicine" came on. It stood out, given all the unscientific and devastatingly harmful nonsense from #RFKJr and co., particularly his #eugenics against #autistic people and recent announcement falsely tying #acetaminophen use during pregnancy to #autism, while simultaneously furthering his long record of #misogyny. Despite the song character's claims, pain often requires more than #placebos. https://youtu.be/0mWM0S1dMro?si=_Jx1uK_Vx3QdzVLk
Girl, You Have No Faith In Medicine

YouTube

Immer mehr Kinder und Jugendliche leben mit #Adipositas. Ein Grazer Forschungsteam erforscht nun einen neuen Ansatz, mit dem Kinder ihren Appetit besser regulieren können. Sie arbeiten mit offenen #Placebos als Intervention für Kinder mit Übergewicht. #scilog

https://scilog.fwf.ac.at/magazin/kann-der-placeboeffekt-kindern-beim-abnehmen-helfen

Kann der Placeboeffekt Kindern beim Abnehmen helfen?

Der Placeboeffekt funktioniert auch dann, wenn transparent ist, dass ein Mittel keinen Wirkstoff enthält. Ein Grazer Forschungsteam untersucht diesen Ansatz nun als Intervention für Kinder mit Übergewicht. Erste Studien zeigen, dass offene Placebos den Appetit zügeln können – doch die Idee polarisiert.

scilog - Das Magazin des Wissenschaftsfonds FWF
Love this work! #Placebos more effective when patients aware. Would #rct double-blind protocols also have an impact? #MedSci
https://ebm.bmj.com/content/early/2025/03/05/bmjebm-2024-112875
Efficacy of open-label placebos for premenstrual syndrome: a randomised controlled trial

Objective To investigate the efficacy and safety of open-label placebos (OLP) in premenstrual syndrome (PMS). Design Randomised controlled trial. Setting Switzerland, 2018–2020. Participants 150 women (18–45 years of age) with PMS or premenstrual dysphoric disorder. Intervention Random assignment (1:1:1) to treatment as usual (TAU), OLP without treatment rationale (OLP–), or OLP with treatment rationale (OLP+). OLP consisted of two placebo pills per day for 6 weeks. Main outcome measures Primary outcomes were PMS symptom intensity and interference between groups across three menstrual cycles (MC1–MC3); adverse events (ie, safety) were measured at weeks 3 and 6 after the start of the intervention. Secondary outcomes were psychological and somatic subscales of PMS symptom intensity, and adherence. Results From 2 August 2018 to 3 December 2020, 150 women were randomly allocated to TAU (n=50), OLP– (n=50), and OLP+ (n=50), of whom 145 (96.7%) completed trial participation. Groups differed in symptom intensity (F(4)=4.419, p=0.002, r2=0.16) and interference (F(4)=3.159, p=0.014, r2=0.13) across three MCs. Mean symptom intensity at MC3 was lower for OLP+ compared to TAU (b=–9.97, SE=2.85, t(412)=3.50, p<0.001, d=0.90) and to OLP– (b=–6.10, SE=2.89, t(411)=2.11, p=0.036, d=0.55), but OLP– and TAU did not differ (b=–3.87, SE=2.87, t(411)=1.35, p=0.177, d=0.35). Mean interference at MC3 was lower for OLP+ compared to TAU (b=–1.23, SE=0.54, t(443)=2.30, p=0.022, d=0.55) and to OLP– (b=–1.10, SE=0.54, t(442)=2.02, p=0.044, d=0.48), but OLP– and TAU did not differ (b=–0.14, SE=0.54, t(442)=0.26, p=0.799, d=0.06). Four non-serious adverse events were reported in OLP– (n=1) and OLP+ (n=3). Improvement in psychological and somatic symptom intensity was comparable to primary outcomes. Adherence to the OLP intervention was high (93.18±18.95%), with no difference between groups. Conclusions The results of our clinical trial indicate that OLP provided with a treatment rationale is an effective, safe, and acceptable treatment for PMS. Trial registration ClinicalTrials.gov [NCT03547661][1] (submitted 2 May 2018). Data are available in a public, open access repository. Meta-data is openly accessible on the data repository Harvard Dataverse. Upon reasonable request, relevant anonymised participant-level data will be made available. [1]: /lookup/external-ref?link_type=CLINTRIALGOV&access_num=NCT03547661&atom=%2Febmed%2Fearly%2F2025%2F03%2F05%2Fbmjebm-2024-112875.atom

BMJ Evidence-Based Medicine
All Placebos are not created equal

Have you ever heard of a Perkins Tractor? If you lived in London in the 18th Century, you could buy a pair of Perkins Tractors (shown above) for the steep price of five guineas, and wave them over an aching part of your body for about twenty minutes as a way of relieving your pain. They worked, sort of. People who bought and used Perkins Tractors

Samstack
My #hypochondria's so bad my doctor prescribes me broad spectrum #placebos.
We can learn a lot from an RCT of open-label #Placebos for #WeightLoss. But not that they're a "promising" treatment for #obesity.
https://conscienhealth.org/2024/10/the-remarkable-power-of-an-open-label-placebo-for-weight-loss/
The Remarkable Power of an Open-Label Placebo for Weight Loss - ConscienHealth

Why does an RCT of open label placebos for weight loss in overweight and mild obesity seem to have an effect?

ConscienHealth

#DoktorWhatson

Warum redet keiner über #Placebos?!

“#Homöopathie wirkt nicht über den #Placebo_Effekt hinaus.”

Was bedeutet das eigentlich? Das haben wir mit der Hilfe zweier Experten recherchiert und es stellt sich heraus: es gibt tatsächlich etwas, das die #Medizin von der Homöopathie lernen kann.
https://www.yewtu.be/watch?v=tpVVCQrOdJw